According to a post on the FDA’s website, BioMarin receives orphan designation for its treatment of patients with hypertrophic cardiomyopathy with a mutation in the MYBPC3 gene.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN: